RHO and retinitis pigmentosa 1: Its aim is to assess the safety, tolerability, efficacy, and life quality after one dose of subretinal injection of SPVN06 in the patients with rod–cone dystrophies (including RP) caused by the mutation in the RHO, PDE6A, or PDE6B gene [70] (Figure 1) (Table 1).